Citigroup Reaffirms “Neutral” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “neutral” rating reaffirmed by stock analysts at Citigroup in a note issued to investors on Tuesday, January 9th, Marketbeat.com reports. They currently have a $388.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $380.00. Citigroup’s price target points to a potential upside of 4.43% from the company’s current price.

Other analysts have also issued reports about the company. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Credit Suisse Group reaffirmed a “buy” rating and set a $485.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. UBS Group dropped their target price on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating on the stock in a research report on Thursday, September 21st. Guggenheim reaffirmed a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, October 23rd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $540.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, November 13th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Regeneron Pharmaceuticals has an average rating of “Hold” and an average price target of $471.11.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $0.25 during trading on Tuesday, reaching $371.53. The company had a trading volume of 661,818 shares, compared to its average volume of 660,649. Regeneron Pharmaceuticals has a 52-week low of $340.09 and a 52-week high of $543.55. The firm has a market capitalization of $39,920.00, a PE ratio of 33.74, a P/E/G ratio of 1.44 and a beta of 1.52. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 earnings per share. analysts predict that Regeneron Pharmaceuticals will post 13.55 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. National Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 3.1% in the second quarter. National Asset Management Inc. now owns 856 shares of the biopharmaceutical company’s stock worth $421,000 after purchasing an additional 26 shares during the period. Suntrust Banks Inc. lifted its position in Regeneron Pharmaceuticals by 1.9% in the second quarter. Suntrust Banks Inc. now owns 3,194 shares of the biopharmaceutical company’s stock worth $1,568,000 after purchasing an additional 59 shares during the period. Thrivent Financial For Lutherans lifted its position in Regeneron Pharmaceuticals by 2.2% in the second quarter. Thrivent Financial For Lutherans now owns 2,850 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 60 shares during the period. Raymond James Trust N.A. lifted its position in Regeneron Pharmaceuticals by 8.6% in the second quarter. Raymond James Trust N.A. now owns 899 shares of the biopharmaceutical company’s stock worth $441,000 after purchasing an additional 71 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in Regeneron Pharmaceuticals by 2.9% in the second quarter. Rafferty Asset Management LLC now owns 3,111 shares of the biopharmaceutical company’s stock worth $1,528,000 after purchasing an additional 87 shares during the period. Hedge funds and other institutional investors own 66.63% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Citigroup Reaffirms “Neutral” Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/19/regeneron-pharmaceuticals-regn-neutral-rating-reiterated-at-citigroup.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply